Table 1 Reviewer discrepancies with chemotherapy response status

From: A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

Change to final response status

Reviewer 1 agrees with final response status

Reviewer 2 agrees with final response status

MRD to pCR

1 (1%)

1 (1%)

pCR to MRD

3 (2%)

4 (2%)

CRNG to MRD

6 (4%)

1 (1%)

MRD to CRNG

1 (1%)

37 (22%)

CRNG to NC

9 (5%)

47 (28%)

NC to CRNG

8 (5%)

18 (11%)

NR to CRNG

1 (1%)

3 (2%)

MRD to NC

1 (1%)

10 (6%)

NC to MRD

3 (2%)

 

MRD to NR

 

1 (1%)

NC to NR

 

1 (1%)

NR to NC

 

9 (5%)